PA
CCCC icon

Perceptive Advisors’s C4 Therapeutics CCCC Stock Holding History

Perceptive Advisors’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-766,231
Closed -$6.72M – 99
2022
Q3 		$6.72M Hold
766,231
– – 0.2% 74
2022
Q2 		$5.78M Sell
766,231
-1,316,492
-63% -$11.6M 0.18% 77
2022
Q1 		$50.5M Sell
2,082,723
-126,190
-6% -$3.06M 1.01% 26
2021
Q4 		$71.1M Sell
2,208,913
-49,653
-2% -$1.96M 1.1% 24
2021
Q3 		$101M Hold
2,258,566
– – 1.47% 17
2021
Q2 		$85.5M Sell
2,258,566
-900,000
-28% -$32.2M 1.11% 23
2021
Q1 		$117M Hold
3,158,566
– – 1.48% 20
2020
Q4 		$105M Buy
+3,158,566
New +$91.6M 1.12% 25

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors's CCCC Position: Q4 2022 in Review

Perceptive Advisors sold out of C4 Therapeutics (CCCC) in Q4 2022, closing a stake of 766,231 shares — an estimated $6.72M sold.

Perceptive Advisors first reported a position in CCCC in Q4 2020 and held it in 8 quarters. The position peaked at $117M in Q1 2021. 117 funds tracked by Wall St. Rank hold CCCC as of Q4 2022.

  • Perceptive Advisors reported no remaining C4 Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Perceptive Advisors sold 766,231 C4 Therapeutics shares in Q4 2022, an estimated $6.72M.
  • Perceptive Advisors first reported a position in C4 Therapeutics in Q4 2020 and held it in 8 quarters.
  • Perceptive Advisors's C4 Therapeutics position peaked at $117M in Q1 2021.
  • 117 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2022.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.